SEPSIS Testing Market: By Product (Blood Culture Media, Instruments, Assay Kits and Reagents), By Pathogen ( Bacterial Sepsis, Viral Sepsis, Fungal Sepsis, Other), By Test Type Analysis ( Laboratory tests, Point of Care Tests), By Technology (Microbiology, Molecular Diagnostics, Immunoassay, Flow Cytometry), By End User (Hospitals and Clinics, Diagnostic Labs, Homecare, Others), and By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) and forecast to 2030.

Sepsis Diagnostic Market size was valued at USD 943.3 million in 2023 and is poised to grow at a CAGR of 7.6% from 2024-2030. Sepsis is an acute condition in which the body's reaction to an infection destroys its tissues. Bacterial infections are among the most prevalent causes. Other infections, including viral and fungal infections, can also cause this condition. There are three phases of the disease: sepsis, severe sepsis, and septic shock. According to WHO, 30 million people are estimated to get affected by sepsis every year. Due to an increase in the prevalence of sepsis which may lead to organ dysfunction and death in severe cases, early identification is needed. The increasing numbers of sepsis development cases and spreading awareness are the major factors that are driving the growth of the global market over the forecast timeframe. However, the lack of awareness and facilities in low- and middle-income countries, the high cost of testing, and the lack of favorable reimbursement policies are hampering the growth of the tuberculosis testing market in the forecast years.

However, Regulatory bodies have also played a crucial role, recently there has been a series of approvals of sepsis testing products. Efforts to increase public awareness through campaigns and hospital treatment have been made to levitate the restrains. According to CDC reports, ICU infections have doubled in number over the last 5 years. According to WHO, 7 out of 100 patients develop hospital-acquired infections in developing countries. The rising number of pneumonia cases and awareness among the public are the main opportunities of this market. COVID-19 has had a great impact on the sepsis testing market, cause during that period sepsis prompt tests increased substantially.

Recent Development In The Sepsis Testing Market:

• In June 2023, Prenosis Inc. received a BARDA contract to study the utility of its sepsis diagnostic tool.

• In January 2023, Cytovale, a medical diagnostics company announced that its IntelliSep test has received U.S. Food and Drug Administration (FDA) clearance to aid in the early detection of sepsis for the approximately 30 million adult patients with signs and symptoms of infection who present to US emergency departments (ED) each year.
• In November 2023, Inflammatix completed the technical development of its point-of-care TriVerity Acute Infection and Sepsis Test System. It also received the U.S. FDA’s breakthrough device designation for that system. The firm hopes to launch the test in the fourth quarter of 2024.